Skip to main content
Top
Published in: International Cancer Conference Journal 2/2021

01-04-2021 | Thrombocytopenia | Case report

Histiocytic sarcoma following combination chemotherapy for primary mediastinal germ cell tumor: a diagnostic dilemma

Authors: Hiroshi Yaegashi, Yuki Kato, Takahiro Nohara, Kouji Izumi, Yoshifumi Kadono, Tohru Miyagi, Takao Nakashima, Kaori Yoshimura, Yasunori Sato, Kenichi Harada, Atsushi Mizokami

Published in: International Cancer Conference Journal | Issue 2/2021

Login to get access

Abstract

Histiocytic sarcoma is considered an extremely rare condition. We herein report on a case of histiocytic sarcoma following combination chemotherapy for a primary mediastinal germ cell tumor in a 26-year-old Asian man who visited the General Medicine Department of a hospital with complaints of cough and high fever. Chest computed tomography (CT) imaging revealed a tumor (diameter 10.5 cm) in the anterior mediastinum, with no signs of metastasis, and CT-guided biopsy of the mediastinal tumor revealed the presence of some necrotic cartilages. The patient’s serum α-fetoprotein (AFP) level was determined to be high at 160.4 ng/mL and a primary mediastinal non-seminomatous germ cell tumor was suspected, so the patient was referred to the Department of Urology. Despite the presence of severe thrombocytopenia, the patient was treated using a combination of chemotherapy and intermittent transfusion, which was able to normalize his serum AFP level. However, resection of the mediastinal tumor was unsuccessful due to persistent thrombocytopenia and the patient was subsequently transferred to our hospital for further examination and treatment. Despite management by hematologists, the condition of the patient did not improve; although his AFP level remained normal, the tumor increased in size and then metastasized to the liver and spleen. The general condition of the patient deteriorated and he died 9 months after his first visit. The patient was diagnosed with histiocytic sarcoma following a pathological autopsy. Due to the extremely rare incidence of histiocytic sarcoma, this condition should be a differential diagnosis and the appropriate tests must be conducted to give an exact treatment.
Literature
1.
go back to reference Moch H et al (eds) (2016) WHO classification of tumours of the urinary system and male genital organs, 4th edn. IARC Press, Lyon Moch H et al (eds) (2016) WHO classification of tumours of the urinary system and male genital organs, 4th edn. IARC Press, Lyon
2.
go back to reference Pileri SA, Grogan TM, Harris NL et al (2002) Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology 41:1–29CrossRef Pileri SA, Grogan TM, Harris NL et al (2002) Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology 41:1–29CrossRef
3.
go back to reference Takahashi E, Nakamura S (2013) Histiocytic sarcoma: an updated literature review based on the 2008 WHO classification. J Clin Exp Hematop 53:1–8CrossRef Takahashi E, Nakamura S (2013) Histiocytic sarcoma: an updated literature review based on the 2008 WHO classification. J Clin Exp Hematop 53:1–8CrossRef
4.
go back to reference Song SY, Ko YH, Ahn G (2005) Mediastinal germ cell tumor associated with histiocytic sarcoma of spleen: case report of an unusual association. Int J Surg Pathol 13:299–303CrossRef Song SY, Ko YH, Ahn G (2005) Mediastinal germ cell tumor associated with histiocytic sarcoma of spleen: case report of an unusual association. Int J Surg Pathol 13:299–303CrossRef
5.
go back to reference Sohn BS, Kim T, Kim JE et al (2010) A case of histiocytic sarcoma presenting with primary bone marrow involvement. J Korean Med Sci 25:313–316CrossRef Sohn BS, Kim T, Kim JE et al (2010) A case of histiocytic sarcoma presenting with primary bone marrow involvement. J Korean Med Sci 25:313–316CrossRef
6.
go back to reference Sood R, Mehta A, Bansal D et al (2019) Mediastinal mixed germ cell tumor with splenic histiocytosis: a rare coincidence. Indian J Pathol Microbiol 62:341–342CrossRef Sood R, Mehta A, Bansal D et al (2019) Mediastinal mixed germ cell tumor with splenic histiocytosis: a rare coincidence. Indian J Pathol Microbiol 62:341–342CrossRef
7.
go back to reference Shinoda H, Yoshida A, Teruya-Feldstein J (2009) Malignant histiocytoses/disseminated histiocytic sarcoma with hemophagocytic syndrome in a patient with mediastinal germ cell tumor. Appl Immunohistochem Mol Morphol 17:338–344CrossRef Shinoda H, Yoshida A, Teruya-Feldstein J (2009) Malignant histiocytoses/disseminated histiocytic sarcoma with hemophagocytic syndrome in a patient with mediastinal germ cell tumor. Appl Immunohistochem Mol Morphol 17:338–344CrossRef
8.
go back to reference Fang LH, Shih LS, Lee PI et al (2016) Mediastinal germ cell tumor-associated histiocytic proliferations treated with thalidomide plus chemotherapy followed by alemtuzumab-containing reduced intensity allogeneic peripheral blood stem cell transplantation: a case report. Medicine 95:e2515CrossRef Fang LH, Shih LS, Lee PI et al (2016) Mediastinal germ cell tumor-associated histiocytic proliferations treated with thalidomide plus chemotherapy followed by alemtuzumab-containing reduced intensity allogeneic peripheral blood stem cell transplantation: a case report. Medicine 95:e2515CrossRef
9.
go back to reference Go H, Jeon YK, Huh J et al (2014) Frequent detection of BRAF V600E mutations in histiocytic and dendritic cell neoplasms. Histopathology 65:261–272CrossRef Go H, Jeon YK, Huh J et al (2014) Frequent detection of BRAF V600E mutations in histiocytic and dendritic cell neoplasms. Histopathology 65:261–272CrossRef
10.
go back to reference Michonneau D, Kaltenbach S, Derrieux C et al (2014) BRAF V600E mutation in a histiocytic sarcoma arising from hairy cell leukemia. J Clin Oncol 32:e117–e121CrossRef Michonneau D, Kaltenbach S, Derrieux C et al (2014) BRAF V600E mutation in a histiocytic sarcoma arising from hairy cell leukemia. J Clin Oncol 32:e117–e121CrossRef
11.
go back to reference Idbaih A, Mokhtari K, Emile J-F et al (2014) Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. Neurology 83:1478–1480CrossRef Idbaih A, Mokhtari K, Emile J-F et al (2014) Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. Neurology 83:1478–1480CrossRef
12.
go back to reference Branco B, Comont T, Ysebaert L et al (2019) Targeted therapy of BRAF V600E-mutant histiocytic sarcoma: a case report and review of the literature. Eur J Haematol 103:444–448CrossRef Branco B, Comont T, Ysebaert L et al (2019) Targeted therapy of BRAF V600E-mutant histiocytic sarcoma: a case report and review of the literature. Eur J Haematol 103:444–448CrossRef
13.
go back to reference Diamond EL, Subbiah V, Lockhart AC et al (2018) Vemurafenib for BRAF V600–mutant erdheim-chester disease and langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol 4:384–388CrossRef Diamond EL, Subbiah V, Lockhart AC et al (2018) Vemurafenib for BRAF V600–mutant erdheim-chester disease and langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol 4:384–388CrossRef
Metadata
Title
Histiocytic sarcoma following combination chemotherapy for primary mediastinal germ cell tumor: a diagnostic dilemma
Authors
Hiroshi Yaegashi
Yuki Kato
Takahiro Nohara
Kouji Izumi
Yoshifumi Kadono
Tohru Miyagi
Takao Nakashima
Kaori Yoshimura
Yasunori Sato
Kenichi Harada
Atsushi Mizokami
Publication date
01-04-2021
Publisher
Springer Singapore
Published in
International Cancer Conference Journal / Issue 2/2021
Electronic ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-020-00467-7

Other articles of this Issue 2/2021

International Cancer Conference Journal 2/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine